COMMUNIQUÉ DE PRESSE publié le 08/08/2024 à 10:00, il y a 1 année 10 mois SphingoTec Closes €5M Series C to Accelerate Market Development and Financial Growth with Innovative Biomarkers SphingoTec secures €5M Series C funding led by Think.Health Ventures to drive global expansion and commercialize innovative biomarkers for critical care, aiming for improved patient outcomes Funding Biomarkers SphingoTec Critical Care Series C
BRÈVE publiée le 18/06/2024 à 10:05, il y a 2 années SphingoTec Introduces PenKid at AKI & CRRT Course in Vicenza SphingoTec Biomarker AKI Kidney Function PenKid
BRÈVE publiée le 18/06/2024 à 10:05, il y a 2 années SphingoTec présente PenKid au cours AKI & CRRT à Vicence SphingoTec Biomarqueur AKI Fonction Rénale StyloKid
COMMUNIQUÉ DE PRESSE publié le 18/06/2024 à 10:00, il y a 2 années Advancing Kidney Care With Solidified Evidence – SphingoTec Presents PenKid at AKI & CRRT Course in Vicenza SphingoTec introduces kidney function biomarker PenKid at AKI & CRRT Course. PenKid addresses AKI diagnostic gaps with real-time assessment and risk prediction capabilities SphingoTec PenKid Kidney Function Biomarker AKI & CRRT Course Biomarker Integration
BRÈVE publiée le 26/03/2024 à 13:05, il y a 2 années 3 mois SphingoTec annonce des changements majeurs dans sa direction Biomarqueurs Innovations Diagnostiques Changements De Gestion SphingoTec Soin Critique
BRÈVE publiée le 26/03/2024 à 13:05, il y a 2 années 3 mois SphingoTec Announces Major Management Changes Biomarkers Management Changes Diagnostic Innovations SphingoTec Critical Care
COMMUNIQUÉ DE PRESSE publié le 26/03/2024 à 13:00, il y a 2 années 3 mois SphingoTec Announces Management Changes SphingoTec announces changes in management team with new appointments. Deborah Bergmann appointed as CEO. Dr. Florian Uhle as CMO and Nicole Witzmann as CFO. Company aims to enhance critical care diagnostics Management Team Biomarkers SphingoTec Deborah Bergmann Critical Care Diagnostics
COMMUNIQUÉ DE PRESSE publié le 05/10/2023 à 10:00, il y a 2 années 8 mois New Formula Leverages Proenkephalin A 119-159 (penKid) for Improved GFR Estimation in Steady-State and Critically Ill Patients
COMMUNIQUÉ DE PRESSE publié le 06/09/2023 à 10:00, il y a 2 années 9 mois International Experts Highlight Demand for Diagnostic Innovations as PenKid's Research and Real-World Data Fuels Quest for Improved RRT Liberation Tools
COMMUNIQUÉ DE PRESSE publié le 31/08/2023 à 12:30, il y a 2 années 9 mois Boditech Med and SphingoTec close Market Development Agreement to Boost Commercialization of Kidney Function Biomarker PenKid
Publié le 27/06/2026 à 16:50, il y a 17 heures 47 minutes Redwood AI Announces Definitive Agreement with Quantum.IQ and Expands into Quantum Resistant Cyber Security
Publié le 27/06/2026 à 01:40, il y a 1 jour 8 heures Polaris Renewable Energy Announces Results of Director Elections at Annual and Special Meeting
Publié le 27/06/2026 à 00:00, il y a 1 jour 10 heures Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Publié le 26/06/2026 à 23:00, il y a 1 jour 11 heures Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Publié le 26/06/2026 à 22:50, il y a 1 jour 11 heures Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada
Publié le 27/06/2026 à 00:05, il y a 1 jour 10 heures EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss
Publié le 27/06/2026 à 00:04, il y a 1 jour 10 heures Persistent and Nagarro sign Business Combination Agreement to form the Persistent - Nagarro Group, a global leader in AI-led digital engineering
Publié le 26/06/2026 à 23:36, il y a 1 jour 11 heures Persistent and Nagarro sign Business Combination Agreement to form the Persistent – Nagarro Group, a global leader in AI-led digital engineering
Publié le 26/06/2026 à 23:36, il y a 1 jour 11 heures EQS-Adhoc: Nagarro SE: Nagarro signs business combination agreement with Persistent Systems and supports voluntary public takeover offer to all shareholders at EUR 81 per share
Publié le 26/06/2026 à 23:27, il y a 1 jour 11 heures EQS-WpÜG: Takeover Offer / Target company: Nagarro SE; Bidder: Galaxy Germany Holding SE